These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12901232)

  • 1. Alpha v integrin inhibitors and cancer therapy.
    Tucker GC
    Curr Opin Investig Drugs; 2003 Jun; 4(6):722-31. PubMed ID: 12901232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin targeted drug and gene delivery.
    Wang Z; Chui WK; Ho PC
    Expert Opin Drug Deliv; 2010 Feb; 7(2):159-71. PubMed ID: 20095940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrete functional motifs reside within the cytoplasmic tail of alphaV integrin subunit.
    Haas TA
    Thromb Haemost; 2008 Jan; 99(1):96-107. PubMed ID: 18217140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD; Scharf O; Schoenfeldt M
    Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoproteolytic activation of alpha(v) integrin by proprotein convertase PC5 is required for vascular smooth muscle cell adhesion to vitronectin and integrin-dependent signaling.
    Stawowy P; Kallisch H; Veinot JP; Kilimnik A; Prichett W; Goetze S; Seidah NG; Chrétien M; Fleck E; Graf K
    Circulation; 2004 Feb; 109(6):770-6. PubMed ID: 14970114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting.
    Manzoni L; Belvisi L; Arosio D; Civera M; Pilkington-Miksa M; Potenza D; Caprini A; Araldi EM; Monferini E; Mancino M; Podestà F; Scolastico C
    ChemMedChem; 2009 Apr; 4(4):615-32. PubMed ID: 19212960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
    Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
    J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion.
    Nystrom ML; McCulloch D; Weinreb PH; Violette SM; Speight PM; Marshall JF; Hart IR; Thomas GJ
    Cancer Res; 2006 Nov; 66(22):10833-42. PubMed ID: 17108119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells.
    Samanna V; Wei H; Ego-Osuala D; Chellaiah MA
    Exp Cell Res; 2006 Jul; 312(12):2214-30. PubMed ID: 16631740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
    Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P; Knight LC; Welch MJ
    Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
    Kim JW; Lee HS
    Int J Mol Med; 2004 Oct; 14(4):529-35. PubMed ID: 15375578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus vectors targeting alphaV integrin or heparan sulfate receptors display different distribution of transgene activity after intramuscular injection.
    Cirielli C; Serino F; Straino S; Toietta G; Abeni D; Ventoruzzo G; Orlando G; Mazzanti P; Melillo G; Whickham TJ; Kovesdi I; Biglioli P; Gaetano C; Capogrossi MC
    J Gene Med; 2004 Mar; 6(3):309-16. PubMed ID: 15026992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
    Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin inhibitors reaching the clinic.
    Stupp R; Ruegg C
    J Clin Oncol; 2007 May; 25(13):1637-8. PubMed ID: 17470853
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.